MedPath

Role of Dexamethasone for Erector Spinae Plane Block in Patients Undergoing Total Abdominal Hysterectomy

Not Applicable
Completed
Conditions
Postoperative Pain
Interventions
Registration Number
NCT03769818
Lead Sponsor
Aswan University Hospital
Brief Summary

The aim to study the efficacy of bupivacaine 0.25% with dexamethasone and that of bupivacaine 0.25% alone for erector spinae plane block for postoperative analgesia in patients undergoing total abdominal hysterectomy Group 1: bupivacaine 0.25% + dexamethasone 8 mg

* Group 2: bupivacaine 0.25%

* Group3: control group A prospective Randomized Interventional double-blind study.

Detailed Description

Optimal dynamic analgesia is recognized as the key to enhanced recovery following open abdominal surgery. In the last decade, there has been a significant shift away from thoracic epidural analgesia (TEA) that has been long considered as the gold standard. Various techniques have tried to replicate the analgesic efficacy of TEA. They include transversus abdominis plane analgesia (TAP), rectus sheath analgesia (RS), wound infusion analgesia (WI) and trans muscular quadratus lumborum analgesia. However, each of these techniques has specific limitations that prevent them from being the analgesic technique of choice for all open abdominal surgeries. Chin et al first described the erector spinae plane (ESP) block for providing analgesia following ventral hernia repair. The unique feature of the ultrasound-guided truncal blocks is that in all of these techniques, in contrast to peripheral nerve blocks, no nerve or plexus needs to be identified: Local anesthesia (LA) is injected in a particular muscle plane, in which the injectate spreads and reaches the intended nerves. This simple mechanism has made delivery of nerve blocks easy and versatile.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
150
Inclusion Criteria
  • Women ranging age between 30-60 years a who undergoing elective total abdominal hysterectomy
Exclusion Criteria
  • Participants had known sensitivity to bupivacaine
  • Participants had difficulty in intubation
  • Participants were on chronic pain medication or already on long-term opioids
  • Participants smokers
  • Participants with disabilities who were unable to communicate pain levels
  • refuse to consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
bupivacaine and dexamethasonebupivacaineBilateral ESP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
bupivacaine and dexamethasonedexamethasoneBilateral ESP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
bupivacaine and placebo to dexamethasonebupivacaineBilateral ESP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
bupivacaine and placebo to dexamethasoneplacebo to dexamethasoneBilateral ESP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
control groupplacebo to dexamethasoneBilateral ESP block with placebo to bupivacaine bilaterally plus placebo to dexamethasone
control groupplacebo to bupivacaineBilateral ESP block with placebo to bupivacaine bilaterally plus placebo to dexamethasone
Primary Outcome Measures
NameTimeMethod
Visual analog score for pain during movement24 hours post operative

movement-evoked pain measurements ranging from 0 to 10, where 0 no pain and 10 maximum pain

Secondary Outcome Measures
NameTimeMethod
number of days patients stay in hospital4 weeks

calculation of number of days patients stay in hospital

Visual analog score for pain during rest24 hours postoperative

ranging from 0 to 10, where 0 no pain and 10 maximum pain

number of patients need Fentanyl consumption24 hours postoperative

calculation of the number of patients need Fentanyl consumption

Trial Locations

Locations (1)

Aswan University

🇪🇬

Aswan, Egypt

© Copyright 2025. All Rights Reserved by MedPath